A Look at Eli Lilly’s Valuations on June 25
Eli Lilly (LLY) is one of the leading global drug manufacturers, and it operates under two segments—Human Pharmaceuticals and Animal Health Products. Eli Lilly surpassed Wall Street analysts’ estimates for earnings per share and revenues for the first quarter and reported EPS of $1.34 on revenues of $5.7 billion during the quarter.